International Collaborations

• T-Cell 2.0 – observational international registry of patients with newly diagnosed peripheral T-cell lymphoma.
• Global NLPHL One Working Group (GLOW) Initiative
• Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Current Projects

• Effect of substitution of platinum chemotherapy in adults with relapsed or refractory non-Hodgkin lymphoma in routine clinical practice (recruiting)
• Exploring care pathways and developing predictive models for B-cell non-Hodgkin lymphomas outcomes in Australia
• Gastrointestinal involvement and bowel perforation in lymphoma – prevalence and management in Australia
• High risk diffuse large B-cell lymphoma in younger patients: treatment patterns and outcomes
• Obesity prevalence and clinical associations in Australian lymphoma patients
• Treatment outcomes in treatment-naive and relapsed and refractory T cell/histiocyte rich large B cell lymphoma with a focus on outcomes following novel approaches
• Real-world outcomes of relapsed and refractory peripheral T cell lymphoma with novel therapeutic agents: A multicentre international registry analysis led by the Australian and New Zealand Lymphoma and Related Diseases Registry (LaRDR)
• RT Inhibitor Study – Influence of anti-retroviral prophylaxis on outcomes after R-CHOP chemotherapy in DLBCL

Completed Projects

• Adolescent and young adult, Waldenström macroglobulinemia, testicular lymphoma projects
• A review of the patterns of treatment and survival outcomes for patients with large B-cell lymphoma in Australia
• Characteristics of Hodgkin lymphoma in Australia
• Chronic Lymphocytic Leukaemia data analysis (Scholarly Intensive Placement for Medical Students)
• Front-line treatment of elderly patients with classical Hodgkin lymphoma: a multicentre retrospective analysis from the ALA and LaRDR
• GELF criteria project
• Melbourne Genomics Health Alliance Lymphoma Flagship
• Movember cancer registries platform
• Ibrutinib follow-up named patient program (NPP) analyses for CLL and MCL
• WhiMSICAL – Waldenstrӧm Macroglobulinaemia Study Involving Cart-wheeL
• Immunoglobulin use and outcomes in Chronic lymphocytic leukaemia And Non-Hodgkin lymphoma – The ICAN Study
• Long-term outcomes in patients with SMZL treated in the Rituximab Era
• Real-world Experience of Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B Cell Lymphoma

The Australasian Lymphoma Alliance (ALA)

The ALA has been in a long-term research partnership with the LaRDR. We value our collaboration with the ALA.

GLOW: Global nLPHL One Working GROUP

GLOW is a current LaRDR partner looking to collect data on nodular lymphocyte-predominant Hodgkin lymphoma.

HoLISTIC: Hodgkin Lymphoma International Study for Individual Care

HoLISTIC is a current LaRDR partner looking to optimise the clinical care of Hodgkin lymphoma patients.

T-cell Project 2.0

The T-cell Project 2.0 is a current LaRDR partner looking to improve understanding of Peripheral T-cell lymphoma.

2024

• Binkley MS, Flerlage, JE, Savage KJ, Akhtar S, Steiner R, Zhang X, et al. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.23.01655
• Barraclough A, Agrawal S, Talaulikar D, Chong G, Yoo E, Cheah CY, et al. Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. Haematologica. https://doi.org/10.3324/haematol.2023.284538
• Shaw B, Chung E, Wellard C, Yoo E, Bennett R, Birks C, et al. Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. eJHaem.2024;1–8.https://doi.org/10.1002/jha2.870

2023

• Al-Mashhadi AL, Simonsen MR, Cheah CY, Amini R, Arboe B, Cerhan JR, et al. Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up, Presentation at: 2023 ASH Annual Meeting; 2023 December 9-12.
• Evens AM, Rodday AM, Maurer MJ, Advani R, Andre M, Gallamini A, et al. Development and Validation of the Early-Stage Hodgkin Lymphoma International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium, Presentation at: 2023 ASH Annual Meeting; 2023 December 9-12.
• Maurer MJ, Parsons SK, Upshaw JN, Rodday AM, Friedberg JW, Gallamini A, et al. Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium, Presentation at: 2023 ASH Annual Meeting; 2023 December 9-12.
• Hapgood G, Civallero M, Stepanishyna Y, Vose JM, Cabrera ME, Advani RH, et al. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Blood Adv 2023; bloodadvances.2023010037. doi: https://doi.org/10.1182/bloodadvances.2023010037
• Wong E, Wellard C, Rady K, Talaulikar D. Real-world data on lymphoma in adolescents and young adults (AYA) – report from the Lymphoma and Related Diseases Registry (LaRDR). Oral presentation: Canberra Health Annual Research Meeting 2023; 2023 July 18 -21; Canberra, Australia.
• Manni M, Chiattone CS, Prince HM, Pavlovsky A, Tomuleasa C, Miranda E, et al. Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T-cell Project 2.0, Poster presentation at: 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi; 2023 June 13-17; Lugano, Switzerland.
• Shaw B, Chung E, Wellard C, Yoo E, Bennett R,  Birks C, et al. Polatuzumab, bendamustine & rituximab (Pola-BR) efficacy in relapsed/refractory trial-ineligible large B cell lymphoma patients: An Australian Lymphoma Registry (LaRDR) study, Abstract Book at: 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi; 2023 June 13-17; Lugano, Switzerland.
• Shaw B, Chung E, Wellard C, Yoo E, Bennett R,  Birks C, et al. Polatuzumab, bendamustine & rituximab (Pola-BR) efficacy in relapsed/refractory diffuse large B cell lymphoma (RRDLBCL) trial-ineligible patients: an Australian Lymphoma Registry (LaRDR) study, Abstract Library at: European Hematology Association;  2023 June 8-15; Frankfurt, Germany.
• Goh Z, Latimer M, Lewis KL, Cheah CY, Di Ciaccio P, Cushion T, et al. Characteristics and Outcomes of Older Patients with Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study, Clinical Lymphoma, Myeloma and Leukemia. 2023. doi: https://doi.org/10.1016/j.clml.2023.01.014

2022

• Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Wong Doo N et al. Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. Eur J Haematol. 2022; 1– 10. doi:10.1111/ejh.13915
• Baggio D, Wellard C, Chung E, Talaulikar D, Keane C, Opat S et al. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry, Leukemia & Lymphoma, DOI: 10.1080/10428194.2022.2157676
• Rodday AM, Parsons SK, Friedberg JW, Gallamini A, Hawkes E, Hodgson DC, et al. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Development and Validation of a Clinical Prediction Model from the HoLISTIC Consortium. Journal of Clinical Oncology. 2022 Nov 10. Available from: https://doi.org/10.1200/JCO.22.02473
• Goh Z, Latimer M, Lewis KL, Cheah CY, Di Ciaccio PR, Cushion T, et al. Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study, Presentation at: 2022 ASH Annual Meeting; 2022 December 10-13.
• Rodday AM, Parsons SK, Friedberg JW, Gallamini A, Hawkes EA, Hodgson DC, et al. Development and Validation of the Advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Blood. 2022 Nov 15;140(Supplement 1):760-2.
• Lymphoma and Related Diseases Registry Investigators. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Medical Research Methodology. 2022 Oct;22:266
• Ratnasingam S, Mutsando H, Hawkes E, Wood E, Wellard C, Chung E, Opat S. Patient characteristics and management of aggressive lymphoma in metropolitan and non-metropolitan centres in Australia from the Lymphoma and Related Diseases Registry (LaRDR), Presentation at: BLOOD 2022; 2022 September 11-14.
• Wong E, Wellard C, Rady K, Talaulikar D. Real-world data on lymphoma in adolescents and young adults (AYA) – report from the Lymphoma and Related Diseases Registry (LaRDR), Presentation at: BLOOD 2022; 2022 September 11-14.
• Bhopal S, Chung E, Wellard C, Anderson M, Hawkes E, Mulligan S, Wood E. Defining the demographics, clinical presentation, and management of Australian patients with chronic lymphocytic leukaemia (CLL) on the Lymphoma and Related Diseases Registry (LaRDR), 2016 to 2021, Presentation at: BLOOD 2022; 2022 September 11-14.
• Goh Z, Latimer M, Lewis KL, Cheah C, Di Ciaccio PR, Cushion T, et al. Characteristics and Outcomes of Elderly Patients with classicial Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Diseases Registry (LaRDR) Study, Presentation at: BLOOD 2022; 2022 September 11-14.
• Chai K, Chung E, Cheah C, Crassini K, Crispin P, Cushion T, et al. Infection patterns and outcomes in patients with newly diagnosed CLL and NHL – Preliminary results from the Immunoglobulin use and Outcomes in CLL and NHL (ICAN) study, Presentation at: BLOOD 2022; 2022 September 11-14.

2021

• Walker SK, Harrop S, Di Ciaccio P, Lewis KL, Boles R, Tedjaseputra A, Hamad N, Hodges G, Yannakou CK, Tam CS, Opat S, Cheah CY, Ku M; Real World Data on the Outcomes of Richter’s Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study, Presentation at: American Society of hematology 2021; 2021 December 10-14.
• Baggio D. Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian context: an analysis of the Lymphoma and Related Diseases Registry, Presentation at: 13th Annual T-cell Lymphoma Forum 2021; 2021 July 8-10.
• Baggio D, St George G, Chung E, Waters N, Wood E, McQuilten Z, et al. Ibrutinib in relapsed/refractory chronic lymphocytic leukaemia: interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry, Poster session presented at: BLOOD 2021; 2021 September 20-23; Adelaide, Australia.
• Baggio D, St George G, Chung E, Waters N, Wood E, McQuilten Z, et al. Ibrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL): interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry, Poster session presented at: BLOOD 2021; 2021 September 20-23; Adelaide, Australia.
• Baggio D, St George G, Chung E, Waters N, Wood E, McQuilten Z, et al. Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian cohort: an analysis of the Lymphoma and Related Diseases Registry (LaRDR), Poster session presented at: BLOOD 2021; 2021 September 20-23; Adelaide, Australia.
• Federico M, Chiattone CS, Prince HM, Pavlovsky A, Manni M, Civallero M, et al. Subtypes of mature T and NK cell lymphomas according to 2016 WHO classification. Preliminary report of the International Prospective T-cell Project 2.0. Hematological Oncology, 39.
• Federico M, Chiattone CS, Prince HM, Pavlovsky A, Manni M, Civallero M, et al. Subtypes of mature T and NK cell lymphomas according to 2016 WHO classification. Preliminary report of the International Prospective T-cell Project 2.0, E-poster gallery at: 16th International Conference on Malignant Lymphoma; 2021 June 18-22; Lugano, Switzerland.
• Opat S, St George G, Wellard C, Chung E, Berkahn L, Cheah C, et al. Real world management of Lymphoma and Related diseases in Australia: The first five years of the Lymphoma and Related Diseases Registry (LaRDR), Poster session presented at: BLOOD 2021; 2021 September 20-23; Adelaide, Australia.
• Nguyen J, St George G, Chung E, Waters N, Wood E, McQuilten Z, et al. Clinical characteristics of Australian treatment-naïve classical Hodgkin Lymphoma (cHL) patients from the Lymphoma and Related Diseases Registry (LaRDR), Poster session presented at: BLOOD 2021; 2021 September 20-23; Adelaide, Australia.
• Shipton M, Wellard C, St George G, Chung E, Waters N, McQuilten Z, et al. Patterns of treatment and outcomes in patients with large B-cell lymphoma: The Australian real-world experience, Presentation at: BLOOD 2021; 2021 September 20-23; Adelaide, Australia.

2020

• Hawkes E. Achieving International Guidelines on PTCL: Are we closer to Global Standards of Care? The Australian TCL landscape, Presentation at: International TCL forum; 2020 February 3; San Diego, United States. 
• Maqbool MG, Tam CS, Morison IM, Simpson D, Mollee P, Schneider H, et al. A practical guide to laboratory investigations at diagnosis and follow up in Waldenström Macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology. 2020 Feb 1;52(2):167-78

2019

• Barraclough A, Hawkes E, Churilov L. Utility of GELF criteria in treatment decisions for follicular lymphoma (FL) treated in clinical practice, Poster session presented at: BLOOD 2019; 2019 October 20-23; Perth, Australia.
• Barraclough A, Yoo E, Cheah CY, Talaulikar D, Nguyen B, Turner M, et al. The ‘Real World’ Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative, Blood 2019; 134 (Supplement_1).
• Barraclough A, Yoo E, Cheah CY, Talaulikar D, Nguyen B, Turner M, et al. The ‘Real World’ Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative, Poster session presented at: 61st ASH Annual Meeting; 2019 December 7-10; Florida, United States of America.
• Clugston S, Hall D, Gangatharan S. Decision-making in CNS prophylaxis for DLBCL in a single institution, Poster session presented at: BLOOD 2019; 2019 October 20-23; Perth, Australia.
• Tohidi-Esfahani I, Warden A, Malunis E, DeNardis P, Bomsztyk J, D’Sa S, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study In CArt-wheeL): A Global Patient-derived Data Registry mapping treatment and quality of life data, Poster session presented at: ICML 2019; 2019 June 18-22; Lugano, Switzerland.
• Tohidi-Esfahani I, Warden A, Malunis E, DeNardis P, Bomsztyk J, D’Sa S, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study In CArt-wheeL): A Global Patient-derived Data Registry mapping treatment and quality of life data, Poster session presented at: The 24th European Hematology Association Congress; 2019 June 13-16; Amsterdam, The Netherlands.
• Tohidi-Esfahani I, Warden A, Malunis E, DeNardis P, Bomsztyk J, D’Sa S, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-derived Data Registry Mapping Treatment and Quality of Life. Hematol Oncol, 37: 234-235.
• St George G, Wellard C, Berkahn L, Cheah C, Dickinson M, Gandhi M, et al. The Lymphoma and Related Diseases Registry (LaRDR): A post-pilot update, Paper presented at: BLOOD 2019; 2019 October 20-23; Perth, Australia.
• Yoo E, Lewis K, Joske D, Cull G, Crawford J, Radeski D, et al, Treatment patterns and outcomes of patients with follicular lymphoma (FL) at Sir Charles Gairdner Hospital (SCGH): An analysis of data from the Lymphoma and related diseases registry (LaRDR), Poster session presented at: BLOOD 2019; 2019 October 20-23; Perth, Australia.

2018

• Dickinson M, Hawkes E, Berkahn L, Cheah C, Gandhi M, Giri P, et al, High rates of early treatment failure in diffuse large B-cell lymphoma: early results from the Lymphoma and Related Diseases Registry, Poster session presented at: BLOOD 2018; 2018 October 21-24; Brisbane, Australia.
• Tohidi-Esfahani I, Warden A, Malunis E, DeNardis P, Bomsztyk J, D’Sa S, et al. WhiMSICAL (Waldenström’s aldenström’s Macroglobulinemia Study Involving CArt-wheeL): A Global WM Registry for the Patient’s Voice A Global WM Registry for the Patient’s Voice, Poster session presented at: 10th International Workshop on Waldenström’s Macroglobulinemia; 2018 October 11-13; New York, United States of America.
• Xu K, Rowsell L, Tahir F, Hall L, Opat S, Wood E, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study Involving CArt-wheeL): Creating robust patient-reported data for observational research, Poster session presented at: BLOOD 2018; 2018 October 21-24; Brisbane, Australia.
• Talaulikar D, Lade S, Kumar B, Juneja S, Morey A, Jain S et al. A national pathology review committee for the Lymphoma and Related Diseases Registry, Poster session presented at: RCPA Pathology Update 2018; 2018 March 2-4; Sydney, Australia.

2017

• Rowsell L, Kel G,  Berkahn L, Cheah C, Dickinson M, Gandhi M, et al. The Lymphoma and Related Diseases Registry (LaRDR): Improving the quality of care for lymphoma patients, Poster session presented at; HAA 2017; 2017 October 29 –November 1; Sydney, Australia.
• Tohidi-Esfahani I, Warden A, deNardis P, Tam C, Scott C, Trotman J. WhiMSICAL (Waldenström’s Macroglobulinemia Study Involving CArt -wheeL) update: Empowering patients internationally to contribute data for research, Paper presented at: HAA 2017; 2017 October 29 –November 1; Sydney, Australia.

2016

• Morrison J, Berkahn L, Dickinson M, Gandhi M, Giri P, Hertzberg M, et al. Real world management of lymphoma: Development of the Australian and New Zealand Lymphoma and Related Diseases Registry (LaRDR), Poster session presented at: HAA 2016; 2016 November 13-16; Melbourne, Australia.